EUVIMEDEUVIMED entdecken
Crossref

Development of a Long-Acting FAPI Dimer Albb-2FAPI for Diagnosis and Therapy of FAP-Positive Tumors

Mengqi Shi, Xuejun Wen, Yucen Tao, Jingjing Zhang iD, Xiaoyuan Chen iD

Molecular Pharmaceutics · 03.08.2026 · 23 (8) · 4144-4154

DOI: 10.1021/acs.molpharmaceut.6c00178 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 16.07.2026. Verfasst von Mengqi Shi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore119074, Singapore. Hauptthemen laut MEDLINE: Lutetium, Gelatinases, Membrane Proteins, Serine Endopeptidases. Die Arbeit nennt 42 Literaturangaben. Gefördert von: National Research Foundation, National Medical Research Council, National University of Singapore.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fibroblast activation protein (FAP)-targeted radiotheranostics show strong promise for cancer imaging and therapy, yet their clinical translation is limited by the trade-off between rapid tumor targeting and insufficient systemic residence time. To address this challenge, we report the design and evaluation of 177Lu-Albb-2FAPI, a long-acting dimeric FAPI derivative that integrates FAPI-02 dimerization with an Evans Blue-based reversible albumin-binding motif to achieve improved tumor targeting while preserving a favorable pharmacokinetic profile. Molecular docking revealed enhanced FAP binding via avidity-driven stabilization without compromising albumin interaction. In vitro studies confirmed rapid, FAP-specific cellular uptake, while in vivo SPECT/CT imaging and biodistribution analyses demonstrated higher and more sustained tumor accumulation, together with improved early tumor-to-background contrast, compared with the monomeric analogue Albb-1FAPI. In the Panc02 tumor model, characterized by moderate FAP expression, 177Lu-Albb-2FAPI exhibited durable tumor retention and induced rapid tumor regression while preserving hematological safety. By coupling dimerization-enhanced target engagement with controlled albumin binding, 177Lu-Albb-2FAPI overcomes key diagnostic and therapeutic limitations of existing long-acting FAP radioligands, establishing a refined molecular design strategy for next-generation FAP-targeted radiotheranostics with strong translational potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LutetiumGelatinasesMembrane ProteinsSerine EndopeptidasesRadiopharmaceuticalsRadioisotopesNeoplasmsAnimalsHumansFibroblast Activation Protein AlphaMiceCell Line, TumorEndopeptidasesXenograft Model Antitumor AssaysTissue DistributionFemaleMolecular Docking SimulationSingle Photon Emission Computed Tomography Computed Tomography

Stichwörter der Autor:innen

177LuAlbb-2FAPIFAPdimerizationradiotheranostics

Substanzen

Fibroblast Activation Protein AlphaLutetiumEndopeptidasesGelatinasesMembrane ProteinsSerine EndopeptidasesRadiopharmaceuticalsRadioisotopesLutetium-177

Autor:innen und Institutionen

  • Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore119074, Singapore.
  • Center for Nuclear Medicine and Molecular Imaging (CNMMI), Shandong Cancer Hospital and Institute, Jinan250117, China.

ORCID-Profile: Jingjing Zhang, Xiaoyuan Chen

Förderung

  • National Research Foundation
  • National Medical Research Council
  • National University of Singapore
  • Ministry of Education - Singapore

Zitieren

APA

Shi, M., Wen, X., Tao, Y., Zhang, J., & Chen, X. (2026). Development of a Long-Acting FAPI Dimer Albb-2FAPI for Diagnosis and Therapy of FAP-Positive Tumors. Molecular Pharmaceutics, 23(8), 4144-4154. https://doi.org/10.1021/acs.molpharmaceut.6c00178

Vancouver

Shi M, Wen X, Tao Y, Zhang J, Chen X. Development of a Long-Acting FAPI Dimer Albb-2FAPI for Diagnosis and Therapy of FAP-Positive Tumors. Molecular Pharmaceutics. 2026;23(8):4144-4154. doi:10.1021/acs.molpharmaceut.6c00178

BibTeX
@article{Shi2026,
  author = {Shi, Mengqi and Wen, Xuejun and Tao, Yucen and Zhang, Jingjing and Chen, Xiaoyuan},
  title = {Development of a Long-Acting FAPI Dimer Albb-2FAPI for Diagnosis and Therapy of FAP-Positive Tumors},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  volume = {23},
  number = {8},
  pages = {4144--4154},
  doi = {10.1021/acs.molpharmaceut.6c00178}
}
Kostenlos starten →